Table 2 Second-look laparotomy (SLL)

From: Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group

 

No. of evaluable patients ( n =155)

 

Standard (S) n =82

Intensive (I) n =73

SLL (n=114)

63 (77%)

51 (70%)

Findings

pCR

25 (39%)

12 (23%)

Microscopic

11 (17%)

12 (24%)

<2 cm

16 (25%)

15 (29%)

>2 cm

11 (18%)

12 (24%)

Not done (n=41)

19 (23)

22 (30)

Reasons

Stable/progressive disease

4 (21%)

3 (14%)

Early stopping due to toxicity

6 (32%)

7 (32%)

Patient refusal

1 (5%)

3 (14%)

Others

8 (42%)

9 (41%)

  1. Abbreviation: pCR=pathological complete response.